Vas deferens, congenital unilateral aplasia of

Summary

Vas deferens, congenital unilateral aplasia of (MONDO:0800311) is a disease. A subtype of congenital bilateral absence of vas deferens — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vas deferens, congenital unilateral aplasia of
Mondo ID	MONDO:0800311
UMLS	C5393224
MedGen	1712847
GARD	0026494
Is cancer (heuristic)	no

Also known as: CUAVD

Disease family

This is a subtype of congenital bilateral absence of vas deferens. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › congenital bilateral absence of vas deferens › vas deferens, congenital unilateral aplasia of

Related subtypes (2): congenital bilateral aplasia of vas deferens from CFTR mutation, vas deferens, congenital bilateral aplasia of, X-linked

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.